Physician profile
Marcy W Epstein
NPI 1326371105
$4,113.91
in general payments reported to CMS, 2019-2025
10 companies · $2,125 in 2025
The $2,125 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $600 · 2022: $352 · 2023: $715 · 2024: $323 · 2025: $2,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,075 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,075.20 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $826.35 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $816.46 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $716.32 | 2024-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $657.29 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $403.60 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $398.94 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $119.77 | 2022-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $102.00 | 2021-2022 | |
| Lundbeck LLC | $53.29 | 2023-2025 | Abilify Maintena |
| Luye Pharma (USA) LTD. | $19.89 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.